Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia

Neuropsychopharmacology

Volumn 27, Issue 3, 2002, Pages 479-497

  Smith, Robert C ^a,b   Singh, Abhay ^b   Infante, Mauricio ^b   Khandat, Amaresh ^b   Kloos, Angelica ^a,b,c  

^a MANHATTAN PSYCHIATRIC CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

Cognitive function; Negative symptoms; Nicotine; Schizophrenia; Smoking

Indexed keywords

NICOTINE;

ADULT; ANXIETY; ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DRUG EFFECT; EVALUATION; EXPERIMENTAL DESIGN; FEMALE; HUMAN; MALE; MENTAL PATIENT; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL; REACTION TIME; SCHIZOPHRENIA; SPATIAL ORIENTATION; STATISTICAL SIGNIFICANCE; TASK PERFORMANCE; TREATMENT OUTCOME; VERBAL MEMORY;

ADMINISTRATION, INTRANASAL; ADULT; ANALYSIS OF VARIANCE; BLOOD PRESSURE; COGNITION; COTININE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GANGLIONIC STIMULANTS; HUMANS; MALE; MEMORY, SHORT-TERM; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NICOTINE; SCHIZOPHRENIA; SMOKING; TREATMENT OUTCOME;

EID: 0036711193     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(02)00324-X     Document Type: Article

References (56)

1. Adler L.E., Hoffer L.D., Wiser B.A., Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry. 150:1993;1856-1861.
2. Adler L.E., Hoffer L.J., Griffith J., Waldo M.C., Freedman R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry. 32:1992;607-616.
3. Andreasen N. The Scale for Assessment of Negative Symptoms (SANS). 1983;University of Iowa, Iowa City.
4. Bell R.C.H., Smith R.C. Tardive dyskinesia. characterization and prevalence in a statewide system J Clin Psychiatry. 39:1978;39-47.
5. Berlin I., Said S., Spreux-Varoquaux O., Olivares R., Launay J.-M., Puesch A.J. Monoamine oxidase a and b activities in heavy smokers. Biol Psychiatry. 38:1995;756-761.
6. Dalack G.W., Becks L., Hill E., Pomerleau O., Meador-Woodruff J.H. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology. 21:1999;195-202.
7. Dalack G.W., Healy D.J., Meador-Woodruff J.H. Nicotine dependence in schizophrenia. clinical phenomena and laboratory findings Am J Psychiatry. 155:1998;1490-1501.
8. Dalack G.W., Meador-Woodruff J.H. Smoking, smoking withdrawal and schizophrenia. case reports and a review of the literature Schizophrenia Rsch. 22:1996;133-141.
9. Damsma G., Day J., Fibiger H.C. Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens. Eur J Pharmacol. 168:1989;363-368.
10. Davis R.A. The determination of nicotine and continine in plasma. J Chromatographic Science. 24:1986;134-141.
11. de la Fuente-Fernandez R., Ruth T.J., Sossi V., Schulzer M., Calne D.B., Stossi A.J. Expectation and dopamine release. mechanism of the placebo effect in Parkinson's disease Science. 293:2001;1164-1166.
12. Domino E.F. Tobacco smoking and nicotine neuropsychopharmacology. some future research Directions Neuropsychopharmacology. 18:1998;456-468.
13. Fagerstrom K., Schneider N. Measuring nicotine dependence. A review of the Fagerstrom tolerance questionnaire J Behav Med. 12:1989;159-181.
14. Fowler J.S., Volkow N.D., Wang G.-J., Pappas N., Logan J., MacGregor R., Axeloff D., Shea C., Schyler D., Wolf A.P., Warner D., Zebulkova I., Cliento R. Inhibition of monoamine oxidase B in the brains of smokers. Nature. 379:1996;733-736.
15. Freedman R., Coon H., Myles-Worsley M., Orr-Utreger A., Olincy A., Davis A., Polymeropoulos M., Holik J., Hopkins J., Hoff M., Rosenthal J., Waldo M.C., Reimherr F., Wender P., Yaw J., Young D.A., Breese C.R., Adams C., Patterson D., Adler L.E., Kruglyak L., Leonard S., Byerley W. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proceedings National Academy Sciences. 94:1997;587-592.
16. George T., Vessicchio J., Sahady D., Head C., Termine A., Bregartner T., Kosten T., Wexler B. Effects of smoking abstinence on cognitive function in schizophrenia (abst.). Biol Psychiatry. 49:2001;5S. a.
17. George T., Ziedonis D.M., Feingold A., Pepper W.T., Satterburg C.A., Winkel J., Rounsaville B.J., Kosten T.R. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 157:2001;1835-1842. b.
18. Glassman A. Cigarette smoking. Implications for psychiatric illness Am J Psychiatry. 150:1993;546-553.
19. Goff D.C., Henderson D.C., Amico E. Cigarette smoking and schizophrenia. Relationship to psychopathology and medication side effects Am J Psychiatry. 149:1992;1189-1194.
20. Greenhoff J., Aston-Jones G., Svensson T. Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol Scand. 128:1986;351-358.
21. Hall R.G., Duhamel M., Clanahan R., Miles G., Nason C., Rosen S., Schiller P., Tao-Yonenaga L., Hall S.M. Level of functioning, severity of illness, and smoking status among chronic psychiatric patients. J Nerv Men Dis. 183:1995;468-471.
22. Hamera E., Schneider J., Deviney S. Alcohol, cannabis, nicotine and caffeine use and symptom distress in schizophrenia. J Nerv Men Dis. 183:1995;559-565.
23. Heishman S.J., Taylor R.C., Henningfeld J.E. Nicotine and smoking. A review of effects on human performance Exp Clin Psychopharmacol. 2:1994;345-395.
24. Kay S.R., Fizzbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bull. 13:1987;261-276.
25. Keefe R., Silva S., Perkins D.O., Lieberman J.A. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia. A review and meta-analysis Schizophr Bull. 25:1999;201-222.
26. Levin E. Nicotinic systems and cognitive functions. Psychopharmacology (Berl). 108:1992;417-431.
27. Levin E.D., Wilson W., Rose J.E., McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology. 15:1996;429-436.
28. Lezak M. Neuropsychological Assessment. 1983;Oxford University Press, New York.
29. McGehee D.S., Role L.W. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol. 57:1995;521-546.
30. Meltzer H., McGurk S. The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 25:1999;233-255.
31. Newhouse P.A., Poter A., Kelton M., Corwin J. Nicotinic treatment of Alzheimer's disease. Biol Psychiatry. 49:2001;268-278.
32. Nilsson A., Waller L., Rosengren A., Adlerberth A., Wilhelmsen L. Cigarette smoking is a risk factor for dyskinesias independent of medication exposure. Biol Psychiatry. 41:1997;717-723.
33. O'Brien C.P., Childress A.R., Ehrman R., Robbins S.J. Conditioning factors in drug abuse. can they explain compulsion? J Psychopharmacol. 12:1998;15-22.
34. Olincy A., Ross R.G., Young D.A., Roath M., Freedman R. Improvement in smooth pursuit eye movements after cigarette smoking in schizophrenics. Neuropsychopharmacology. 18:1998;175-185.
35. Perkins K., Grobe J., Fonte C., Breus M. "Paradoxical" effects of smoking on subjective stress versus cardiovascular arousal in males and females. Pharm Biochem Behav. 42:1992;301-311.
36. Perkins K., Sextiob J., Stiller R., Fonte C., DiMarco A., Goettler J., Scierka A. Subjective and cardiovascular responses to nicotine combined with caffeine during rest and casual activity. Psychopharmacology (Berl). 113:1994;438-444.
37. Pomerleau C., Pomerleau O. Euphoriant effects of nicotine in smokers. Psychopharmacology (Berl). 108:1992;460-465.
38. Purdon S., Jones B.D.W., Stip E., Labelle A., Addington D., Davis S.R., Brier A., Tollefson G.D. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone or haloperidol. Arch Gen Psychiatry. 57:2000;249-258.
39. Randt C.T., Brown E.R. Administration Manual. Randt Memory Test:1983;New York: Life Science Associates, Bayport.
40. Reeves D., Kane R., Winter K., Ransford K., Pancella R. Automated Neuropsychological Assessment Metrics (ANAM):Test Administration Guide, Version 1.0. 1993;Institute of Mental Health, St. Louis, MO.
41. Rezvani A., Levin E. Cognitive effects of nicotine. Biol Psychiatry. 49:2001;258-267.
42. Saykin A., Gur R.C., Gur R.E., Mozley D., Mozley L., Resnick S., Kester B., Stafiniak P. Neuropsychological function in schizophrenia. selective impairment in memory and learning Arch Gen Psychiatry. 48:1991;618-624.
43. Saykin A., Schatasel D., Gur R., Kester B., Mozley L. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry. 51:1994;124-131.
44. Schneider N. Efficacy of nicotine nasal spray (NNS). a double-blind, placebo controlled trial in smoking cessation, Kabi Research Report:1992;Sweden, Helsingborg.
45. Shrout P.E., Fleiss J.L. intraclass correlation. Uses in assessing rater reliability Psychol Bull. 86:1979;420-428.
46. Simpson G., Angus J.S.W. A rating scale for extrapyramidal side effects. Acta Psychiatria Scandinavia. 212:1970;9-11.
47. Simpson G.M., Shih J.C., Chen K., Flowers C., Kumazawa T., Spring B. Schizophrenia, monoamine oxidase activity, and cigarette smoking. Neuropsychopharmacology. 20:1999;392-394.
48. Smith R., Allen R., Gordon J., Wolff J. A rating scale for tardive dyskinesia and parkinsonian symptoms. Psychopharm Bull. 19:1983;266-276.
49. Smith R.C., Infante M., Ali A., Nigam S. Effects of cigarette smoking on psychopathology scores in schizophrenic patients. An experimental study Substance Abuse. 22:2001;175-185. a.
50. Smith R., Infante M., Singh A., Khandat A. Olanzapine's effects on neurocognitive functioning in medication refractory schizophrenia. International Journal of Neuropsychopharmacology. 4:2001;239-250. b.
51. Stevens K., Kem W.R., Mahnor V.M., Freedman R. Selective alpha-7 nicotinic agonist normalize inhibition of auditory response in DBA mice. Psychopharmacology (Berl). 136:1998;320-327.
52. Sugaya K., Giacobini E., Chiappinelli V.A. Nicotinic acetylcholine receptor subtypes in human frontal cortex. changes in alzhiemer's disease J Neurosci Res. 27:1990;349-359.
53. Sutherland G., Stapleton J.A., Russel M.A.H. Randomized controlled trial of nasal nicotine spray in smoking cessation. Lancet. 340:1992;324-329.
54. Westman E.C., Behm F.M., Rose J.E. Dissociating the nicotine and airway sensory effects of smoking. Pharmacol Biochem Behav. 53:1996;309-315.
55. Wirshing W, Engle J, Levin E (1989): The acute effects of smoking on tardive dyskinesia. Paper presented at New Research Program and Abstracts, San Francisco, CA, p 89.
56. Zeidonis D.M., Kosten T.R., Glazer W.M., Frances R.J. Nicotine dependence and schizophrenia. Hosp Community Psychiatry. 45:1994;204-206.